Sight Sciences Inc (SGHT) Cotización

I expected it and I bought puts in advance of it.
Was easy to predict

Exactly 1 year since the PPS tanked to $1
Which meant that those who held for 1 year to get LTCGT were going to dump

Wow! Big dip today. What is up?

Hmmm below the professionals price estimate of 5.70. Interesting. I guess you were right on that not being correct. It’s looking like it is below 5.70 .,,,

Hmmm below the professionals price estimate of 5.70. Interesting. I guess you were right on that not being correct. It’s looking like it is below 5.70 .,,,

GOOD NEWS

https://finance.yahoo.com/news/single-tearcare-treatment-improved-functional-200500005.html

Nice movement today

Imagine that , it’s back to target price. Maybe the pro knows something about it after all?!

It’s just hit $5.70

It’s closing in on the target price

Hopefully it will bounce back
It beat estimated revenue

Hopefully it will bounce back

Lots of trading post and premarket. Could be another good day. Earnings to be reported on 8/1

https://finance.yahoo.com/news/sight-sciences-report-second-quarter-200500099.html

Looking awesome. Getting close to a 52 week high PPS. I'm up nearly 200% on my $2.98's.

TFSBIGWS!!!

Do you think that hold is referring to not buying the stock? Is that a possibility?

I love the way you have to dialogue with inflammatory language.

Do you think that hold is referring to not buying the stock? Is that a possibility?

I love the way you have to dialogue with inflammatory language.

Only a fool would listen to an analyst who advises holding a stock that's trading $2.25 ABOVE their price target.
CURRENT PRICE $7.95
Price Target $5.70
ANALYST RATING:
HOLD

Oh NO!!!

47,780 shares? Out of the millions they own????

The world is coming to an end!!!

https://finance.yahoo.com/quote/SGHT/insider-roster/

Re: the buyout you speculated about

I’m guessing that Alison Bouerlein, CFO
Jeremy Hayden , David Badawi, CTO, Paul Badawi CEO, and Sam Park CTO who are officers of sght did not know about the merger either.
They all sold shares July 1, 2 2024

47,780 shares at 5.42 to 6.21 average price per share

they're

Oh no, not another UP day!! How many am I supposed to endure?

UP $0.49
+6.27%

ANOTHER 11 month high closing PPS!

Boy- those analysts sure do know what their talking about, don't they!?!?

I guess they don’t know about the buyout:


According to marketbeat:


UPSIDE/ DOWNSIDE
27.1% Downside
$5.70 Price Target

SHORT INTEREST
Bearish
4.09% of Float Sold Short

ANALYST RATING
Hold
2.00 Rating Score

(Sight Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.)

INSIDER TRADING
Selling Shares
$290,061 Sold Last Quarter

Overall marketrank
0.50 out of 5 stars

What happened?

Sight Sciences sets terms for IPO, to raise up to $160.5 million
Published: July 8, 2021 at 6:37 a.m. ET

Sight Sciences Inc. has set terms of its initial public offering, which could value the California-based ophthalmology and optometry company at up to $971.7 million. The company is looking to raise up to $160.54 million, as it is offering 6.98 million shares in the IPO, which is expected to price between $20 and $23 a share.

LOL

Up nearly 3%

Closed at the 11 month high pps

lol

I put more weight into my own projection- that SGHT will be acquired by a larger optical device company, like Alcon, against whom SGHT was recently awarded damages for patent infringement.

https://www.healio.com/news/ophthalmology/20240430/sight-sciences-awarded-34-million-in-patent-infringement-case-against-alcon

Here’s where I got the information:

Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · IEX Real-Time Price · USD

Price Target
5.60 (-27.18%)

Not my analysis, just researching what various experts have suggested about the potential stock movements of sght.

Three different sources have said not to buy and multiple sources have said year price around $6.

What do you think about the fact that the projected profitability is three years away at best?

Perhaps JP Morgen and others that dumped all their stock was because of this:

Financial Efficiency
Return on equity (ROE) is -44.50% and return on invested capital (ROIC) is -38.09%.

I believe that would be a good call

That makes so much sense

7 analysts have a target of $5.60, which is $2 BELOW the current PPS, and yet, the 7 analysts recommending holding?

So- they recommend holding so as to lock in a 30% LOSS?
BRILLIANT!!!!

RC_702
Re: None
Monday, July 15, 2024 9:25:07 AM
Post# of 80 Go
Analyst Forecast
According to 7 analysts, the average rating for SGHT stock is "Hold." The 12-month stock price forecast is $5.6, which is a decrease of -26.41% from the latest price.

Price Target
$5.6
(-26.41% downside)
Analyst Consensus: Hold[/quote]

Analyst Forecast
According to 7 analysts, the average rating for SGHT stock is "Hold." The 12-month stock price forecast is $5.6, which is a decrease of -26.41% from the latest price.

Price Target
$5.6
(-26.41% downside)
Analyst Consensus: Hold

Before you buy stock in Sight Sciences, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sight Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Perhaps JP and others dumped their shares because of this:

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.

I guess that’s what you could consider a good call

Sorry, but it was not my call. I’m not an expert but I can read what the experts have stated

I guess you’re referring to JP Morgan dumping all of their shares recently being a good call

GOOD CALL!!!
12 Month Price Target usd 6.10
Based on 4 analysts
Price Volatility. High
Last updated: 6/12/2024
On 6/12 the PPS closed @ $6.86

On Friday the PPS closed @ $7.61

That's more than a 10% gain in 1 month

Oh, and BTW, a 25% gain for my $2.98 shares.

it seems they were all wrong to sell and forecast lower
Closed on Friday at an 11 month high PPS

I'm laughing all the way to the bank
1 YEAR CHART

Or perhaps it was:

Operating Income % is Gross Profit minus Operating Expenses. Shown as a percentage of Revenue. A good indicator of profitability. Higher is better.

SGHT OI
2023 - 77.06 %
2022 - 117.70%

Or:

Net Profit % shows how much of each dollar in Revenue translates into Profit. Shown as a percentage of Revenue. Higher is better.

SGHT Net Profit
2023 -68.53%
2022 - 120.90%

And analysts say that they are not going to be profitable for at least three years

Perhaps it was this:

12 Month Price Target usd 6.10
Based on 4 analysts
Price Volatility. High
Last updated: 6/12/2024
Industry Recommendation. Hold

What do they know about the company that made them dump the stock recently?

JPMorgan Chase decreased stake by 12.86% to

LMAO!!!

UP 30% since your post.

Earnings Trend: SGHT is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.

Insider trading , why did:
D1 capital partners LD on 26 Dec23
Sell $16,712,931 of sight sciences?
Entity: company
Shares: 2,852,036
Max Price: $5.86

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.
Yahoo finance June 14, 2024

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.
Yahoo finance June 14, 2024

SGHT under $10

Wow- somebody took a bunch of profit in the last minutes. First down day is quite a while

And another up day.

First time SGHT closed above $7 in over 6 months!!!

She broke through seven dollars. very strong volume today. So bright I gotta wear shades

Good news...

creates big gains. Blue skies ahead. My $2.98's have doubled+

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced the publication of the twelve-month results from the SAHARA trial.

Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops (“Restasis”) had additional clinically meaningful improvements in the signs and symptoms of dry eye disease (“DED”) when crossed over to TearCare. These improvements persisted for six months through month twelve without continued Restasis use.

“Phase 2 of the RCT again demonstrates the clinical effectiveness of TearCare. It also shows that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when TearCare is used as a primary or secondary treatment for DED,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences.

Phase 1 of the SAHARA RCT included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis1. In Phase 2 of the SAHARA RCT, 163 patients who had been randomized and treated with Restasis during phase 1 were crossed over to TearCare at the six-month visit and followed for six months through Month 12 of the study.

Data from the first six months of the SAHARA RCT demonstrated that TearCare, an interventional eyelid procedure for DED, was superior at all measured time points to twice daily use of Restasis for the improvement of tear break up time (“TBUT”), the trial’s primary dry eye signs endpoint and a key measure of tear stability1. TearCare was superior to Restasis in multiple other objective measures of dry eye, and demonstrated clinically meaningful improvements in several symptoms that matched or surpassed Restasis at all measured time points.

The aim of phase 2, undertaken in months six through twelve, was to demonstrate that cessation of Restasis followed by a single TearCare procedure would result in improved signs and symptoms for patients beyond what was achieved with six months of Restasis.